17:03 , Oct 26, 2018 |  BC Week In Review  |  Financial News

Antibiotics play Qpex launches with Medicines Co. assets, BARDA deal

With $33 million in new series A funding, a portfolio of preclinical assets from The Medicines Co. (NASDAQ:MDCO) and a BARDA deal, Qpex Biopharma Inc. (San Diego, Calif.) hopes to begin clinical studies of multiple...
15:56 , Oct 26, 2018 |  BioCentury  |  Finance

Rempex remix

New Enterprise Associates led Qpex Biopharma Inc.’s $33 million A round in hope that the management team will repeat its performance at Rempex Pharmaceuticals Inc. and The Medicines Co. (NASDAQ:MDCO) with a preclinical anti-infectives portfolio....
12:02 , Oct 22, 2018 |  BC Extra  |  Financial News

Antibiotics play Qpex launches with Medicines Co. assets, BARDA deal

With $33 million in new series A funding, a portfolio of preclinical assets from The Medicines Co. (NASDAQ:MDCO) and a BARDA deal, Qpex Biopharma Inc. (San Diego, Calif.) hopes to begin clinical studies of multiple...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Company News

Cortendo management update

Cortendo AB , Gothenburg, Sweden   Business: Endocrine/Metabolic   Hired: Ruth Thieroff-Ekerdt as CMO, effective Dec. 15, formerly CMO of Aptalis Pharma Inc. , which Forest Laboratories Inc. acquired; Actavis plc subsequently acquired Forest  ...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Clinical News

Photofrin porfimer sodium: SPA received

Pinnacle received an SPA from FDA for a Phase III trial to evaluate Photofrin to treat unresectable advanced perihilar cholangiocarcinoma Bismuth type III/IV. The company expects to begin the trial this half. Photofrin is marketed...
02:08 , Jan 9, 2014 |  BC Extra  |  Top Story

Forest to acquire Aptalis

Forest Laboratories Inc. (NYSE:FRX) jumped $10.54 (18%) to $69.30 on Wednesday after announcing it will acquire gastrointestinal company Aptalis Holdings Inc. (Bridgewater, N.J.) for $2.9 billion in cash. The move translates to a $2.8 billion...
01:06 , Dec 27, 2013 |  BC Extra  |  Top Story

Aptalis files for $500 million IPO

Gastrointestinal company Aptalis Holdings Inc. (Mont-Saint-Hilaire, Quebec) filed to raise up to $500 million in an IPO underwritten by Goldman Sachs; JPMorgan; Barclays; and Evercore. Aptalis markets nine products, including Carafate sucralfate suspension to treat...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Company News

Aptalis Pharma, NovaMedica deal

Aptalis granted NovaMedica exclusive rights to develop and commercialize three of Aptalis' gastrointestinal products - Pylera , Lacteol and Panzytrat - in Russia. NovaMedica will complete requirements to obtain regulatory approval in Russia. NovaMedica expects...
01:10 , Oct 25, 2013 |  BC Extra  |  Financial News

Aptalis rumored to be planning IPO after lack of bidder

Gastrointestinal company Aptalis Pharma Inc. (Mont-Saint-Hilaire, Quebec) could not be reached for comment on rumors that the company hired Goldman Sachs and JPMorgan and is planning an IPO slated for next year. According to Reuters,...
07:00 , Oct 7, 2013 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Wk 10/4 Company Bank Analyst Coverage Opinion chg cls Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) Baird Brian Skorney Downgrade Neutral (from outperform) -62% $2.72 Deutsche Bank Alethia Young Downgrade Hold (from buy) Piper...